Logo

OncoBlast-Frontline and Relapsed Management in B-Cell Lymphomas: What the Data Says

This CME-accredited OncoBlast course provides a case-based review of contemporary management strategies for B-cell non-Hodgkin lymphomas. Through real-world clinical scenarios, learners will explore when to initiate treatment, how to interpret landmark trial data, and best practices for integrating targeted therapies and maintenance approaches into personalized care.

Course Accreditations

Course Summary

Events StartsEvents Ends
1/1/202512/31/2025

Faculty

Tycel Phillips   (MD)

Cancer care is a sort of personal mission for Tycel Phillips, M.D. As a teen, he saw how pancreatic cancer affected his grandmother and decided to follow her example of service and make his career helping others as a physician. When he was a medical resident, he lost his mother to breast cancer; her experience with chemotherapy inspired him to pursue research into treatments that are less toxic for patients. His approach to patients is to listen first to understand their needs and develop the most beneficial treatment plan. Dr. Phillips earned his medical degree from Rush University, followed by a residency in internal medicine at the John H. Stroger Jr. Hospital of Cook County in Chicago. His fellowship training in oncology/hematology took place at University Hospitals in Cleveland. Before joining City of Hope, he was a clinical associate professor at the University of Michigan, where he was appointed the Maria Reinhardt DeCesare Research Professor of Blood Cancers and Bone Marrow Transplantation. Leading clinical trials into new targeted therapies is a vital part of Dr. Phillips’ work. He has published over 40 peer-reviewed studies and attracted dozens of research grants. Away from work, Dr. Phillips likes to read, ride his bicycle with his children, exercise and travel.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Genentech Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Abbvie Topic: Research Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Abbvie Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: ADCT Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Astra Zeneca Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Bayer Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Beigene Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: BMS Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Eli Lily Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Epizyme Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Genentech Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Genmab Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Gilead Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Incyte Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Kite Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Pharmacyclics Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Xencor Topic: Advisor Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Pfizer Topic: Advisor

top-curriculum

    Target Audience

  • Medical oncologists
  • Oncology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

    Learning Objectives

    Upon successful completion of this educational activity, participants will be able to:

  • Apply evidence-based criteria to determine when observation is appropriate in indolent and asymptomatic B-cell lymphomas.
  • Interpret clinical trial data to guide frontline and relapsed/refractory treatment decisions, including the use of BTK inhibitors and CAR T-cell therapy.
  • Evaluate the role and limitations of maintenance therapies in improving progression-free and overall survival across B-cell lymphoma subtypes.